A bizonyítékokon alapuló megközelítés fontossága az onkológiában 

• A bizonyítékokon alapuló egészségügyi megközelítés 25 éve Magyarországon
• Onkológiai készítmények klinikai vizsgálati végpontjainak és hatásossági mutatóinak jelentősége a betegek gyógyszer hozzáférésére
• Súlyos hemofíliában szenvedő gyermekek bizonyítékokon alapuló kezelése és gondozása
• Új metrikák az onkológiában túlélési adatok kiértékelésére
• A bizonyítékokon alapuló megközelítés jelentősége a csecsemőkori leukémia terápiájában
• Szisztematikus irodalmi áttekintések és szerepük, WHO prevenciós témájú irányelvfejlesztő munka bemutatása
• Evidencia alapú gyakorlat alkalmazása a gyermekonkológiában: Új lehetőségek és kihívások
• Bizonyítékokon alapuló daganatprevenció
• Daganatos betegek antikoagulálása - bizonyítékokon alapuló megközelítés és a napi gyakorlat
• Bizonyítékokon alapuló orvoslás szerepe az egészségügyi döntéshozatalban
• Bizonyítékokon alapuló irányelvek

• Prof. Dr. Decsi Tamás, PTE KK Magyar Cochrane Tagozat, Gyermekgyógyászati Klinika, igazgató
• Prof. Dr. Boncz Imre, PTE KK, egyetemi tanár, stratégiai elnökhelyettes
• Dr. Györke Eszter, Vas vármegyei Markusovszky Egyetemi Oktatókórház, adjunktus, csecsemő- és gyermekgyógyász szakorvos, gyermek hemato-onkológus szakorvos
• Dr. Ferenci Tamás, Semmelweis Egyetem, Népegészségtani Intézet
• Dr. Csernus Katalin, PTE KK Gyermekgyógyászati Klinika Onkohematológiai Osztály, adjunktus
• Csölle Ildikó Gabriella, PTE ÁOK Népegészségtani Intézet, tanársegéd
• Dr. Garami Miklós, Semmelweis Egyetem II. sz. Gyermekgyógyászati Klinika, egyetemi docens, klinikaigazgató helyettes
• Prof. Dr. Kiss István, PTE ÁOK Orvosi Népegészségtani Intézet, intézetigazgató
• Dr. Endrei Dóra, PTE KK, általános elnökhelyettes
• Dr. Mogyorósy Gábor, DE ÁOK Gyermekgyógyászati Intézet, egyetemi docens 
• Dr. Kis Erika, SZTE ÁOK Bőrgyógyászati és Allergológiai Klinika, egyetemi docens

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation

Why join?
New data from cardiovascular outcomes trials in diabetes have shown that some newer agents have proven CV benefits (e.g. GLP-1 receptor agonists and SGLT2 inhibitors). The compelling evidence has led to significant changes in treatment paradigms as reflected by the new ADA/EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes.

This highly interactive and skills-based Masterclass will provide an opportunity to discuss the rationale and benefits of new clinical approaches and to share experiences with experts in the field of diabetes management.

Sessions will include:
• Strategies for individualizing therapy
• Applying new diabetes therapies with CV benefit in practice 
• Assessing cardiovascular risk 
• Obesity as a treatable condition 
• Instilling confidence in patients in using injectables 
• New formulations on the horizon

How do I join?
The masterclass is free of charge, travel and accommodation will be provided as appropriate.

To submit an application please visit https://integress.cvent.com/ASCENDMasterclass Places are limited.

Invitation